Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) is a clinical stage genetic medicines company whose news flow centers on the development of its lead gene therapy candidate, PBFT02, for neurodegenerative diseases. Company updates frequently highlight progress in the Phase 1/2 upliFT-D trial in frontotemporal dementia with GRN or C9orf72 mutations, including cohort enrollment, dosing milestones, and interim biomarker and safety data.
Investors following PASG news can expect regular announcements of quarterly and annual financial results, where Passage Bio reports research and development spending, general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities, along with commentary on expected cash runway. These releases often include recent business highlights related to PBFT02, such as data readouts on cerebrospinal fluid progranulin levels, plasma neurofilament light chain trends, and protocol amendments intended to refine the benefit–risk profile of the program.
News items also cover regulatory and manufacturing developments, including interactions with the U.S. Food and Drug Administration on analytical comparability for a high-productivity, suspension-based PBFT02 manufacturing process, and plans to seek feedback on potential registrational trial designs. In addition, Passage Bio regularly announces participation in healthcare, genetic medicines, and biopharma investor conferences, where management presents corporate overviews and program updates.
This page aggregates these disclosures, offering a centralized view of Passage Bio’s clinical, regulatory, financial, and corporate communications. Readers interested in PASG can use this news feed to track the evolution of the PBFT02 program, changes in trial design, manufacturing strategy, and key financial and listing-related events such as the company’s reverse stock split and subsequent confirmation of compliance with Nasdaq listing requirements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Passage Bio (Nasdaq: PASG) has granted an inducement award of options to purchase 82,000 shares of its common stock to a new employee, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.05 per share, matching the closing price on the grant date, April 17, 2023. The options will vest over four years, with 25% vesting on the one-year anniversary and the remaining in 36 equal monthly installments, subject to continued employment. The company focuses on developing therapies for central nervous system disorders, including GM1 gangliosidosis and frontotemporal dementia, and has a collaboration with the University of Pennsylvania’s Gene Therapy Program. Further details about its gene therapy pipeline can be found on their official website.
Passage Bio, a clinical stage genetic medicines company focused on central nervous system (CNS) disorders, announced that its CEO William Chou, M.D., and CTO Alex Fotopoulos will participate in a virtual fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 24, 2023, at 3:30 p.m. ET.
The event will be accessible via a live webcast on the company’s website, with a replay available for 30 days after. Passage Bio is dedicated to developing therapies for CNS diseases, currently advancing clinical programs in GM1 gangliosidosis and frontotemporal dementia, and has a robust preclinical pipeline targeting amyotrophic lateral sclerosis and Huntington’s disease. The company collaborates with the University of Pennsylvania’s Gene Therapy Program, enhancing its research capabilities and access to innovative gene therapy candidates.
Passage Bio (NASDAQ: PASG), a clinical stage genetic medicines company, announced that CEO William Chou, M.D., will take part in a fireside chat at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days on April 3, 2023, at 3:55 p.m. ET in New York. A live webcast of the chat will be available on the company's Investors & Media section. Passage Bio focuses on developing transformative therapies for central nervous system (CNS) disorders, including GM1 gangliosidosis and frontotemporal dementia, with strong collaborations enhancing their research capabilities.
Passage Bio (NASDAQ: PASG) reported promising interim data for PBGM01 in GM1 gangliosidosis during the 19th Annual WORLDSymposium™, showing a biological effect in the first six patients. The company plans to expand the Imagine-1 study to include higher doses and expects initial safety data from Cohort 4 by mid-2023. Financial results highlighted a cash position of $189.6 million, sufficient to fund operations through the first half of 2025. The net loss for Q4 2022 stood at $27.1 million, while R&D expenses decreased to $17.7 million. The company anticipates key results from its upliFT-D trial in FTD by late 2023.
Passage Bio, a clinical-stage genetic medicines company (Nasdaq: PASG), announces the opening of its Tachi Yamada Scholarship program for rising juniors majoring in life sciences at Pennsylvania colleges. The $10,000 scholarship, awarded annually, aims to support students committed to careers in life sciences. Applications are due by April 1, 2023, for the initial award in fall 2023. The scholarship honors the legacy of Dr. Tachi Yamada, co-founder and former chairman of the board, who championed mentorship in the field. The selected scholar will also receive mentorship opportunities over two years for professional development.
Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company, announced CEO William Chou will participate in a corporate panel at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 10:30 a.m. ET in Boston, MA. This event will focus on therapies for central nervous system disorders. A live webcast will be accessible on Passage Bio's website, with a replay available for 30 days post-event. The company is advancing treatments for CNS diseases, including GM1 gangliosidosis and frontotemporal dementia, leveraging a collaboration with the University of Pennsylvania's Gene Therapy Program.